Cost-effectiveness analysis of pembrolizumab compared to the standard of care chemotherapy and pembrolizumab combination therapy as first line treatment for PD-L1 positive non-small cell lung cancer in the Slovak Republic

Lung cancer is one of the most common cancers in the world (WHO, 2012). The major risk of a getting  lung cancer is smoking, and second-hand smoking. Every year, more than 8000 people in Slovakia are killed by tobacco-caused disease (Tobacco atlas, 2019) and lung cancer is on the 4th place among the 10 top death causes (Ministry of Health, 2019). Non-small cell lung cancer (NSCLC) represents the most frequent histological type of lung cancers (Novello, et al., 2016). Prognosis of lung cancer is poor with a low overall survival rate, which can be explained by the lack of screening procedures and therefore diagnosis at an advanced stage of the disease.

“Is the immunotherapy treatment with pembrolizumab cost-effective compared to first-line chemotherapy standard treatment or pembrolizumab combination therapy in adult patients with PD-L1 positive non-small cell lung cancer in the Slovak Republic?”

Prosjektbeskrivelse med vedlegg

Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.

TSD

  • Nei
  • Begrunnelse: Data fra literaturen

Biobank

  • Nei

Godkjenninger

Prosjektet har ingen godkjenninger

Prosjektleder / prosjektansvarlig ved UiO

Eline Aas

Ansvarlig enhet

Avdeling for helseledelse og helseøkonomi

Prosjekttype

  • Studentprosjekt – Bachelor-, master- eller spesialistoppgave

Helsefaglig forskning

  • Ja

Personopplysninger

  • Nei

Tidsperiode

  • Start: desember 2019
  • Slutt: oktober 2020